NASDAQ:PRAH - PRA Health Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$81.42 +0.32 (+0.39 %)
(As of 05/22/2018 11:37 AM ET)
Previous Close$81.50
Today's Range$80.94 - $81.63
52-Week Range$69.57 - $95.90
Volume2,806 shs
Average Volume439,253 shs
Market Capitalization$5.14 billion
P/E Ratio25.42
Dividend YieldN/A
Beta0.5

About PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences logoPRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200

Debt

Debt-to-Equity Ratio1.29
Current Ratio0.83
Quick Ratio0.83

Price-To-Earnings

Trailing P/E Ratio25.42
Forward P/E Ratio21.37
P/E Growth1.24

Sales & Book Value

Annual Sales$2.26 billion
Price / Sales2.31
Cash Flow$4.7670 per share
Price / Cash17.08
Book Value$14.78 per share
Price / Book5.51

Profitability

EPS (Most Recent Fiscal Year)$3.20
Net Income$86.92 million
Net Margins4.07%
Return on Equity23.06%
Return on Assets6.84%

Miscellaneous

Employees15,800
Outstanding Shares64,080,000

PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences (NASDAQ:PRAH) issued its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.01. The medical research company earned $701.80 million during the quarter, compared to analysts' expectations of $694.73 million. PRA Health Sciences had a return on equity of 23.06% and a net margin of 4.07%. PRA Health Sciences's revenue was up 43.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 earnings per share. View PRA Health Sciences' Earnings History.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for PRA Health Sciences.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share (EPS) guidance of $4.00-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.12. The company issued revenue guidance of $2.84-2.95 billion, compared to the consensus revenue estimate of $2.91 billion.

What price target have analysts set for PRAH?

11 brokers have issued 1-year price objectives for PRA Health Sciences' stock. Their predictions range from $86.00 to $104.00. On average, they expect PRA Health Sciences' share price to reach $95.1818 in the next twelve months. View Analyst Ratings for PRA Health Sciences.

Who are some of PRA Health Sciences' key competitors?

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the folowing people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 59)
  • Ms. Linda Baddour, Exec. VP, CFO, Corp. Sec. & Principal Accounting Officer (Age 60)
  • Dr. David W. Dockhorn, Exec. VP & Corp. Compliance Officer (Age 57)
  • Michael J. Bonello, Sr. VP of Accounting and Corp. Controller
  • Christine Rogers, Director of PR & Corp. Communications

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Has PRA Health Sciences been receiving favorable news coverage?

News stories about PRAH stock have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PRA Health Sciences earned a daily sentiment score of 0.20 on Accern's scale. They also gave news headlines about the medical research company an impact score of 47.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.66%), Eagle Asset Management Inc. (1.92%), Wells Fargo & Company MN (1.64%), Northern Trust Corp (0.97%), Vaughan Nelson Investment Management L.P. (0.80%) and OppenheimerFunds Inc. (0.79%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

Which major investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., JPMorgan Chase & Co., Federated Investors Inc. PA, Hood River Capital Management LLC, BlackRock Inc., Rock Springs Capital Management LP, American Century Companies Inc. and King Luther Capital Management Corp. Company insiders that have sold PRA Health Sciences company stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

Which major investors are buying PRA Health Sciences stock?

PRAH stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Allianz Asset Management GmbH, Clinton Group Inc., Stephens Investment Management Group LLC, OppenheimerFunds Inc., Prudential Financial Inc., California Public Employees Retirement System and Highland Capital Management LP. View Insider Buying and Selling for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $81.01.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $5.14 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]


MarketBeat Community Rating for PRA Health Sciences (PRAH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  406
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PRA Health Sciences (NASDAQ:PRAH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for PRA Health Sciences in the last 12 months. Their average twelve-month price target is $95.1818, suggesting that the stock has a possible upside of 16.90%. The high price target for PRAH is $104.00 and the low price target for PRAH is $86.00. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.912.912.832.90
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $95.1818$95.1818$91.5833$88.60
Price Target Upside: 16.90% upside6.96% upside0.27% downside8.00% upside

PRA Health Sciences (NASDAQ:PRAH) Consensus Price Target History

Price Target History for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences (NASDAQ:PRAH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$101.00 ➝ $104.00HighView Rating Details
1/31/2018KeyCorpReiterated RatingBuy$100.00LowView Rating Details
1/24/2018MizuhoDowngradeBuy ➝ Neutral$86.00HighView Rating Details
12/15/2017Mitsubishi UFJ Financial GroupInitiated CoverageOverweight$102.00LowView Rating Details
12/11/2017BarclaysInitiated CoverageOverweight ➝ Overweight$94.00MediumView Rating Details
12/1/2017Robert W. BairdSet Price TargetBuy$94.00LowView Rating Details
10/27/2017SunTrust BanksReiterated RatingBuy$101.00N/AView Rating Details
10/26/2017Jefferies GroupReiterated RatingBuy$95.00N/AView Rating Details
8/16/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$89.00LowView Rating Details
8/10/2017CitigroupReiterated RatingBuy$90.00 ➝ $93.00LowView Rating Details
6/26/2017Bank of AmericaInitiated CoverageBuy$89.00LowView Rating Details
2/27/2017Avondale PartnersUpgradeUnderperform ➝ Market Perform$63.00N/AView Rating Details
9/6/2016UBSDowngradeBuy ➝ Neutral$50.00 ➝ $55.00N/AView Rating Details
6/20/2016First AnalysisInitiated CoverageEqual ➝ Equal Weight$47.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

PRA Health Sciences (NASDAQ:PRAH) Earnings History and Estimates Chart

Earnings by Quarter for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences (NASDAQ:PRAH) Earnings Estimates

2018 EPS Consensus Estimate: $3.91
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.76$0.76$0.76
Q2 20182$0.91$0.92$0.92
Q3 20182$0.99$1.05$1.02
Q4 20182$1.17$1.25$1.21

PRA Health Sciences (NASDAQ PRAH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018$0.96N/AView Earnings Details
4/25/2018Q1 2018$0.84$0.85$694.73 million$701.80 millionViewN/AView Earnings Details
2/21/2018Q4 2017$1.02$1.04$543.78 million$568.80 millionViewN/AView Earnings Details
10/25/2017Q3 2017$0.85$0.88$477.89 million$494.55 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.72$0.62$447.79 million$457.90 millionViewListenView Earnings Details
4/25/2017Q1 2017$0.58$0.60$426.81 million$427.08 millionViewN/AView Earnings Details
2/22/2017Q4 2016$0.64$0.71$405.04 million$413.61 millionViewN/AView Earnings Details
11/2/2016Q316$0.64$0.64$394.87 million$399.80 millionViewN/AView Earnings Details
7/28/2016Q2$0.59$0.63$381.25 million$394.20 millionViewListenView Earnings Details
4/27/2016Q116$0.53$0.55$372.21 million$372.30 millionViewListenView Earnings Details
2/24/2016Q4$0.49$0.59$353.42 million$428.90 millionViewListenView Earnings Details
11/2/2015Q3$0.45$0.52$346.05 million$345.10 millionViewListenView Earnings Details
7/27/2015Q215$0.40$0.47$336.74 million$336.50 millionViewListenView Earnings Details
5/6/2015Q115$0.31$0.41$329.80 million$332.00 millionViewListenView Earnings Details
2/18/2015Q414$0.30$0.35$323.50 million$370.00 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

PRA Health Sciences (NASDAQ:PRAH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

PRA Health Sciences (NASDAQ PRAH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.85%
Institutional Ownership Percentage: 99.24%
Insider Trading History for PRA Health Sciences (NASDAQ:PRAH)
Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences (NASDAQ PRAH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Linda BaddourVPSell67,000$90.27$6,048,090.00View SEC Filing  
12/28/2017David W DockhornInsiderSell72,850$90.83$6,616,965.50View SEC Filing  
12/28/2017David W DockhornEVPSell72,850$90.83$6,616,965.5072,850View SEC Filing  
11/16/2017Matthew P YoungDirectorSell5,115$79.90$408,688.50View SEC Filing  
8/14/2017Colin ShannonCEOSell400,000$74.85$29,940,000.00View SEC Filing  
8/14/2017Linda BaddourVPSell100,000$74.85$7,485,000.00View SEC Filing  
8/14/2017Pra Investors L.P. KkrMajor ShareholderSell9,500,000$74.85$711,075,000.00View SEC Filing  
4/17/2017Linda BaddourVPSell196,393$63.59$12,488,630.87124,472View SEC Filing  
3/28/2017Colin ShannonCEOSell50,000$64.00$3,200,000.0050,000View SEC Filing  
3/27/2017David W DockhornInsiderSell85,182$62.00$5,281,284.0055,574View SEC Filing  
2/23/2017Colin ShannonCEOSell100,000$61.50$6,150,000.002,747View SEC Filing  
8/22/2016Colin ShannonCEOSell113,133$51.57$5,834,268.81120,000View SEC Filing  
8/15/2016Linda BaddourVPSell69,380$52.00$3,607,760.0069,380View SEC Filing  
8/12/2016David W. DockhornVPSell107,257$49.00$5,255,593.00View SEC Filing  
5/6/2016Linda BaddourCFOSell92,308$46.70$4,310,783.60View SEC Filing  
5/6/2016Pra Investors L.P. KkrMajor ShareholderSell4,907,692$46.70$229,189,216.40View SEC Filing  
3/8/2016Colin ShannonCEOSell77,019$42.26$3,254,822.94View SEC Filing  
3/8/2016Linda BaddourCFOSell93,000$42.26$3,930,180.00View SEC Filing  
3/8/2016Pra Investors L.P. KkrMajor ShareholderSell4,829,981$42.26$204,114,997.06View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PRA Health Sciences (NASDAQ PRAH) News Headlines

Source:
DateHeadline
$678.55 Million in Sales Expected for PRA Health Sciences (PRAH) This Quarter$678.55 Million in Sales Expected for PRA Health Sciences (PRAH) This Quarter
www.americanbankingnews.com - May 19 at 3:56 AM
ICON (ICLR) versus PRA Health Sciences (PRAH) Head to Head ReviewICON (ICLR) versus PRA Health Sciences (PRAH) Head to Head Review
www.americanbankingnews.com - May 18 at 5:27 AM
Head to Head Contrast: PRA Health Sciences (PRAH) and Luna Innovations (LUNA)Head to Head Contrast: PRA Health Sciences (PRAH) and Luna Innovations (LUNA)
www.americanbankingnews.com - May 17 at 7:40 PM
$0.94 Earnings Per Share Expected for PRA Health Sciences (PRAH) This Quarter$0.94 Earnings Per Share Expected for PRA Health Sciences (PRAH) This Quarter
www.americanbankingnews.com - May 17 at 2:27 PM
IQVIA Has Fallen 2.9%, but Analysts Are Still on BoardIQVIA Has Fallen 2.9%, but Analysts Are Still on Board
finance.yahoo.com - May 17 at 9:18 AM
Financial Review: Luna Innovations (LUNA) versus PRA Health Sciences (PRAH)Financial Review: Luna Innovations (LUNA) versus PRA Health Sciences (PRAH)
www.americanbankingnews.com - May 17 at 1:25 AM
PRA Health Sciences (PRAH) Downgraded to "Hold" at ValuEnginePRA Health Sciences (PRAH) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - May 7 at 10:36 PM
PRA Health Sciences (PRAH) Receives Average Rating of "Buy" from BrokeragesPRA Health Sciences (PRAH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 7 at 1:49 PM
Critical Survey: BTG (BTGGF) versus PRA Health Sciences (PRAH)Critical Survey: BTG (BTGGF) versus PRA Health Sciences (PRAH)
www.americanbankingnews.com - May 6 at 7:41 PM
PRA Named Clinical Research Company of the Year and Makes the Forbes 2018 America’s Best Large Employers ListPRA Named Clinical Research Company of the Year and Makes the Forbes 2018 America’s Best Large Employers List
finance.yahoo.com - May 3 at 4:42 PM
PRA Health Sciences (PRAH) Stock Rating Upgraded by Zacks Investment ResearchPRA Health Sciences (PRAH) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 1 at 9:12 AM
Edited Transcript of PRAH earnings conference call or presentation 26-Apr-18 1:00pm GMTEdited Transcript of PRAH earnings conference call or presentation 26-Apr-18 1:00pm GMT
finance.yahoo.com - May 1 at 9:09 AM
PRA Health Sciences (PRAH) Expected to Announce Quarterly Sales of $712.99 MillionPRA Health Sciences (PRAH) Expected to Announce Quarterly Sales of $712.99 Million
www.americanbankingnews.com - May 1 at 1:46 AM
Contrasting PRA Health Sciences (PRAH) and IQVIA (IQV)Contrasting PRA Health Sciences (PRAH) and IQVIA (IQV)
www.americanbankingnews.com - April 30 at 3:20 PM
Zacks: Brokerages Anticipate PRA Health Sciences (PRAH) to Announce $0.95 Earnings Per ShareZacks: Brokerages Anticipate PRA Health Sciences (PRAH) to Announce $0.95 Earnings Per Share
www.americanbankingnews.com - April 29 at 9:06 PM
PRA Health Sciences (PRAH) Downgraded to "Buy" at BidaskClubPRA Health Sciences (PRAH) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - April 27 at 9:55 AM
BRIEF-Pra Health Sciences Says CFO Linda Baddour To RetireBRIEF-Pra Health Sciences Says CFO Linda Baddour To Retire
www.reuters.com - April 27 at 9:35 AM
PRA Health Sciences (PRAH) CEO Colin Shannon on Q1 2018 Results - Earnings Call TranscriptPRA Health Sciences' (PRAH) CEO Colin Shannon on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 4:43 PM
PRA’s longtime CFO to retirePRA’s longtime CFO to retire
finance.yahoo.com - April 26 at 4:43 PM
PRA Health Sciences (PRAH) Announces Retirement of CFO and Promotion of Michael Bonello to CFOPRA Health Sciences (PRAH) Announces Retirement of CFO and Promotion of Michael Bonello to CFO
www.streetinsider.com - April 26 at 8:57 AM
PRA Health Sciences (PRAH) Announces  Earnings Results, Beats Estimates By $0.01 EPSPRA Health Sciences (PRAH) Announces Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - April 25 at 9:38 PM
PRA Health Sciences (PRAH) Releases FY18 Earnings GuidancePRA Health Sciences (PRAH) Releases FY18 Earnings Guidance
www.americanbankingnews.com - April 25 at 6:28 PM
BRIEF-PRA Health Sciences Q1 GAAP Earnings Per Share $0.59BRIEF-PRA Health Sciences Q1 GAAP Earnings Per Share $0.59
www.reuters.com - April 25 at 4:52 PM
PRA Health Sciences: 1Q Earnings SnapshotPRA Health Sciences: 1Q Earnings Snapshot
finance.yahoo.com - April 25 at 4:52 PM
PRA Health Sciences Announces Retirement of Chief Financial Officer and Promotion of Michael Bonello to CFOPRA Health Sciences Announces Retirement of Chief Financial Officer and Promotion of Michael Bonello to CFO
finance.yahoo.com - April 25 at 4:52 PM
PRA Health Sciences, Inc. Reports First Quarter 2018 ResultsPRA Health Sciences, Inc. Reports First Quarter 2018 Results
finance.yahoo.com - April 25 at 4:52 PM
PRA Health Sciences (PRAH) Set to Announce Quarterly Earnings on MondayPRA Health Sciences (PRAH) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 16 at 3:46 AM
PRA Health Sciences (PRAH) Downgraded by BidaskClubPRA Health Sciences (PRAH) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 9:51 PM
PRA Health Sciences (PRAH) Expected to Post Quarterly Sales of $695.69 MillionPRA Health Sciences (PRAH) Expected to Post Quarterly Sales of $695.69 Million
www.americanbankingnews.com - April 14 at 1:47 AM
Zacks: Analysts Anticipate PRA Health Sciences (PRAH) Will Post Earnings of $0.84 Per ShareZacks: Analysts Anticipate PRA Health Sciences (PRAH) Will Post Earnings of $0.84 Per Share
www.americanbankingnews.com - April 12 at 11:14 PM
PRA Health Sciences (PRAH) PT Raised to $83.00PRA Health Sciences (PRAH) PT Raised to $83.00
www.americanbankingnews.com - April 12 at 8:29 PM
PRA Health Sciences to Report First Quarter 2018 EarningsPRA Health Sciences to Report First Quarter 2018 Earnings
finance.yahoo.com - April 12 at 4:48 PM
PRA Health Sciences (PRAH) Given Average Rating of "Buy" by BrokeragesPRA Health Sciences (PRAH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 1:41 PM
SunTrust Banks Reaffirms Buy Rating for PRA Health Sciences (PRAH)SunTrust Banks Reaffirms Buy Rating for PRA Health Sciences (PRAH)
www.americanbankingnews.com - April 11 at 11:23 PM
PRA Health Sciences (PRAH) Upgraded by Zacks Investment Research to "Buy"PRA Health Sciences (PRAH) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 9 at 9:12 PM
PRA Health Sciences (PRAH) Stock Rating Reaffirmed by KeyCorpPRA Health Sciences (PRAH) Stock Rating Reaffirmed by KeyCorp
www.americanbankingnews.com - April 4 at 2:26 PM
Q4 2018 Earnings Forecast for PRA Health Sciences (PRAH) Issued By First AnalysisQ4 2018 Earnings Forecast for PRA Health Sciences (PRAH) Issued By First Analysis
www.americanbankingnews.com - April 4 at 6:44 AM
Using Social Media To Accelerate Drug Development: The Only Way To Change The ParadigmUsing Social Media To Accelerate Drug Development: 'The Only Way To Change The Paradigm'
finance.yahoo.com - April 3 at 9:22 AM
PRA Health Sciences (PRAH) and Cleveland BioLabs (CBLI) Head-To-Head ContrastPRA Health Sciences (PRAH) and Cleveland BioLabs (CBLI) Head-To-Head Contrast
www.americanbankingnews.com - April 2 at 7:16 PM
Head to Head Analysis: PRA Health Sciences (PRAH) versus BioM�rieux (BMXMF)Head to Head Analysis: PRA Health Sciences (PRAH) versus BioM�rieux (BMXMF)
www.americanbankingnews.com - March 31 at 1:26 PM
PRA Health Sciences (PRAH) Downgraded by Zacks Investment Research to HoldPRA Health Sciences (PRAH) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 31 at 12:49 PM
PRA Health Sciences (PRAH) Lifted to Buy at Zacks Investment ResearchPRA Health Sciences (PRAH) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 3:58 PM
Zacks Investment Research Downgrades PRA Health Sciences (PRAH) to HoldZacks Investment Research Downgrades PRA Health Sciences (PRAH) to Hold
www.americanbankingnews.com - March 29 at 5:48 PM
PRA Health Sciences (PRAH) Lifted to "Buy" at Zacks Investment ResearchPRA Health Sciences (PRAH) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 28 at 9:48 PM
PRA Health Sciences (PRAH) Expected to Post Quarterly Sales of $695.73 MillionPRA Health Sciences (PRAH) Expected to Post Quarterly Sales of $695.73 Million
www.americanbankingnews.com - March 28 at 1:56 AM
PRA Health Sciences (PRAH) Upgraded to "Strong-Buy" by BidaskClubPRA Health Sciences (PRAH) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
PRA Health Sciences (PRAH) Cut to Sell at Zacks Investment ResearchPRA Health Sciences (PRAH) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 2:45 PM
PRA Health Sciences (PRAH) Upgraded to Strong-Buy at BidaskClubPRA Health Sciences (PRAH) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 18 at 4:58 PM
PRA Health Sciences Inc (PRAH) Given Consensus Rating of "Buy" by BrokeragesPRA Health Sciences Inc (PRAH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 1:48 PM
PRA Health Sciences Receives CRO Leadership Award Nasdaq ... - GlobeNewswire (press release)PRA Health Sciences Receives CRO Leadership Award Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 6:08 PM

SEC Filings

PRA Health Sciences (NASDAQ:PRAH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PRA Health Sciences (NASDAQ:PRAH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PRA Health Sciences (NASDAQ PRAH) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.